A Study of ZW251 in Participants With Advanced Solid Tumors

The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

Trial Details

NCT ID
NCT07164313
Phase
PHASE1
Sponsor
Zymeworks BC Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ZW251
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Santa Monica, California, United States|34.01949,-118.49138
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or m…
  • Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and/or metastatic disease
  • Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and/or choriocarcinoma predominant component and locally advan…
  • Measurable disease per RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →